United States: FDA Releases Final Guidance on "Dear Doctor" Letters That Omits Controversial Behavior Modification Assessment Provision

On January 22, 2014, the FDA issued finalized guidance on the use, content and form of Dear Health Care Provider (DHCP) letters. While the finalized guidance modifies and removes certain controversial provisions from the November 2010 draft guidance that called for manufacturers to conduct assessments of the impact of some DHCP letters, the finalized guidance retains an expansive definition of the health care providers who should receive such communications.

The January 2014 finalized guidance, Dear Health Care Providers: Improving Communication of Important Safety Information (Final Guidance), provides the U.S. Food and Drug Administration's (FDA's) recommendations on when manufacturers should issue a DHCP letter, as well as recommendations on the content and format of such letters. Also sometimes referred to as "Dear Doctor" letters, such communications are used by manufacturers to notify health care providers about new or updated information regarding a drug or biologic. The January 2014 guidance finalizes a draft guidance document the FDA had issued on November 12, 2010 (Draft Guidance). In providing context for its recommendations, the agency explains that past studies of DHCP letters found that "the communication quality of the letters—the extent to which the information is accessible and can be understood—has varied widely," and that the recommendations set forth in the Final Guidance stem in part from the findings of such studies, the FDA's own experiences with DHCP letters and the FDA's "general risk communication experience."

Purposes and Types of DHCP Letters

As described in the Final Guidance, DHCP letters constitute one mechanism by which manufacturers notify health care providers of new or updated information—often relating to safety considerations—regarding marketed drugs and biologics (collectively referred to herein as drugs). The Final Guidance limits its discussion of the types of DHCP letters to those that are specifically identified in FDA drug regulations (21 C.F.R. § 200.5), but adds that other types of DHCP letters not specifically enumerated in the regulations may nonetheless be guided by the concepts and regulations in the Final Guidance. Appended to the Final Guidance are model letters for the three specific types of DHCP letters discussed.

Important Drug Warning Letters

The first type of DHCP letter discussed in the Final Guidance is an "Important Drug Warning" letter. Manufacturers must use such letters to communicate new safety information relating to "a significant hazard to health" that may "affect the decision to use a drug or require a change in behavior concerning use of the drug (e.g., a specific type of monitoring)." For example, an Important Drug Warning DHCP letter may be used to communicate information regarding "[p]reviously unknown serious or life-threatening adverse reactions," or the discovery of "a subpopulation in which the drug is contraindicated." The FDA notes that such letters are designed to convey information that would be included in the "BOXED WARNINGS," "CONTRAINDICATIONS" or "WARNINGS AND PRECAUTIONS" sections of a product's labeling.

Important Prescribing Information Letters

The second type of DHCP letter specifically identified in the FDA regulations is an "Important Prescribing Information" letter, used to communicate changes in prescribing information that typically belongs in the "INDICATIONS AND USAGE" or "DOSAGE AND ADMINISTRATION" sections of a drug's labeling. Important Prescribing Information DHCP letters may address, for instance, a change in a drug's dosing or dosage regimen that is "intended to minimize risk or improve effectiveness." The FDA clarifies that an Important Drug Warning letter should be used in lieu of an Important Prescribing Information letter in the event changes to the prescribing information also lead to changes in the information under the "BOXED WARNINGS," "CONTRAINDICATIONS" or "WARNINGS AND PRECAUTIONS" sections of the drug's labeling.

Important Correction of Drug Information Letters

Finally, a manufacturer should use an "Important Correction of Drug Information" DHCP letter "to correct false or misleading information or other misinformation in a prescription drug promotional labeling and advertising that is the subject of a Warning letter or other Agency action." The FDA states that the circumstances under which the agency would require a manufacturer to use an Important Correction of Drug Information letter are beyond the scope of the Final Guidance.

Determining Target Audience

Of particular note, the Final Guidance retains—over objections from several stakeholders—a recommendation from the Draft Guidance that a DHCP letter be sent to not only health care providers who could potentially prescribe the drug at issue (including nurse practitioners and physician assistants with prescribing authority), but any health care provider "likely to" dispense or administer the drug and any other health care provider "who may need to know the information even if they do not prescribe the drug." As the FDA indicated in a July 9, 2013, Federal Register notice, the agency had received a number of comments objecting to these recommendations in the Draft Guidance "as an expansion of the target audience." The FDA responded, however, that the proposed recommendations merely clarify the regulatory requirement that manufacturers convey "important information . . . to physicians and others responsible for patient care," and noted that the recommendations reflect the current reality that "a variety of health care practitioners [are] involved in patient care." The FDA cites as an example emergency departments or primary care physicians who might not prescribe the drug but who might be involved in the care of patients with adverse reactions to prescribed drugs. Likewise, the FDA states that a DHCP letter relating to a new medication guide should be sent to pharmacists, insofar as they are required to distribute the medication guide upon dispensing the drug at issue to a patient.

DHCP Letter Content and Format

In addition to describing the target audience for DHCP letters, the Final Guidance provides detailed recommendations on the information that should be included in a DHCP letter and how such information should be presented. In describing the content of DHCP letters, the Final Guidance includes recommendations for the details that should be in the three particular types of DHCP letters outlined above. The FDA's recommendations, which also apply to electronic DHCP letters where relevant, address the content and format of various components of a DHCP letter, including the information on the envelope and letter heading, in the subject line and in the body of the letter. For example, the Final Guidance clarifies that manufacturers should refrain from providing information or details—such as market information and promotional language—that could distract the reader from the more important information in the letter.

Modifications to Assessment Provisions

In addition to objecting to the recommendations in the Draft Guidance regarding the target audience for DHCP letters, stakeholders also criticized the proposal that manufacturers conduct evaluations of the impact of DHCP letters. Specifically, the Draft Guidance called for manufacturers to evaluate the extent to which a DHCP letter resulted in behavior modification by the target audience to the extent such modifications were intended. Additionally, the FDA recommended that manufacturers ascertain the extent to which the target audience received and is aware of the information conveyed in each DHCP letter.

In comments to the Draft Guidance, stakeholders asserted that the recommendations imposed overly burdensome requirements on manufacturers that were beyond the scope of the FDA's statutory authority and that may have the effect of obscuring the message of DHCP letters by introducing unnecessary additional communications. The FDA conceded the validity of these comments. In the Final Guidance, the agency eliminated the provision that calls for manufacturers to assess the extent to which DHCP letters have the effect of altering the behavior of the target audience as intended. The FDA also revised the recommendation that manufacturers conduct evaluations of the extent to which the target audience received and is aware of the information in a DHCP letter, providing instead that manufacturers should conduct such evaluations "for their own use." Accordingly, under the Final Guidance, manufacturers are not expected to conduct and submit evaluations of DHCP letters for FDA review. The FDA also advises that if the DHCP letter is part of a risk evaluation and mitigation (REMS) requirement for a drug product, there must be an evaluation plan in place under the REMS.

Consultation With the FDA

The FDA encourages manufacturers to work with the relevant review division of the agency on DHCP letters "to ensure that the letter clearly and accurately reflects both the manufacturer's and FDA's understanding of the issue and the action required." Accordingly, in the event a manufacturer learns of new or updated information regarding a drug, early consultation with the FDA may be useful in determining whether a DHCP letter should be issued, the content and format of any such letter, the appropriate target audience for the letter and when the letter should be distributed in light of the issue to which the letter relates.

Considerations for Stakeholders

The Final Guidance provides useful information on the FDA's expectations of the type and content of safety information that should be included in DHCP letters. The FDA correctly removed its initial recommendation that, for letters intended to modify behavior in the target audience, manufacturers assess whether the letter modified behavior as intended. The FDA also modified its recommendation that manufacturers ascertain the extent to which the target audience received and is aware of the information conveyed in each DHCP letter, now recommending that manufacturers conduct these evaluations for "their own use." Finally, the FDA retains its expansive definition of health care providers that should receive DHCP letters to include those non-dispensing providers who "may need to know the information." In view of the new guidance, drug product manufacturers should carefully evaluate their safety reporting programs and assess the impact of these new recommendations and interpretations, including relating to the target audience for particular drug products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.